Inhibitory Effect of Apolipoprotein A-I on Eosinophils in Allergic Rhinitis in vitro and in vivo
Yinhui Zeng,Jinyuan Li,Yueqiang Wen,Haiqing Xiao,Chao Yang,Qingxiang Zeng,Wenlong Liu
DOI: https://doi.org/10.2147/jaa.s449948
2024-02-14
Journal of Asthma and Allergy
Abstract:Yinhui Zeng, 1, &ast Jinyuan Li, 1, &ast Yueqiang Wen, 2, &ast Haiqing Xiao, 1 Chao Yang, 1 Qingxiang Zeng, 1 Wenlong Liu 1 1 Department of Otolaryngology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou, 510623, People's Republic of China; 2 Department of Nephrology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wenlong Liu, Department of Otolaryngology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou, 510623, People's Republic of China, Email Purpose: Eosinophils have pivotal roles in the development of allergic rhinitis (AR) through the release of cytotoxic substances. Apolipoprotein A-I (Apo-AI) exhibits a strong inhibitory effect on eosinophil infiltration in allergic diseases. Nevertheless, the precise impact of Apolipoprotein A-I on eosinophils remains uncertain. Methods: Our study recruited a total of 15 AR children and 15 controls. The correlation between Apo-AI expression and the counts of blood eosinophils was examined. Flow cytometry was employed to assess the role of Apo-AI in eosinophil apoptosis and adhesion. The Transwell system was performed to conduct the migration assay. An animal model using AR mice was established to test the effect of Apo-AI on eosinophils. Results: Serum Apo-AI were negatively related to eosinophils counts and eosinophil chemotactic protein levels in AR. Apo-AI exerts a pro-apoptotic effect while also impeding the processes of adhesion, migration, and activation of eosinophils. The apoptosis triggered by Apo-AI was facilitated through the phosphoinositide 3-kinase (PI3K) pathway. The chemotaxis and activation of eosinophils, which are influenced by Apolipoprotein A-I, are regulated through the PI3K and MAPK signaling pathways. Apo-AI treated mice presented with decreased blood and nasal eosinophilic inflammation as well as down-regulated eosinophil related cytokines. Conclusion: Our findings provide confirmation that Apo-AI exhibits inhibitory effects on the function of eosinophils in allergic rhinitis. This suggests that Apo-AI holds potential as a therapeutic target for future treatment strategies. Keywords: apolipoprotein A-I, eosinophils, allergic rhinitis, apoptosis, adhesion, migration, activation Allergic rhinitis (AR) is a worldwide prevalent condition, with a prevalence rate exceeding 10% of the population. 1 Eosinophils are known to have significant involvement in the pathophysiological mechanisms of AR through the secretion of T helper 2 (Th2) cytokines, which in turn produce type 2 inflammation. 2 Besides, various toxic substance can be released by eosinophils, such as major basic proteins, etc. These proteins have the ability to promote tissue damage and amplify allergic inflammation. 3 Eotaxins, secreted by epithelium after Th2 cytokines stimulation, recruit and activate eosinophils. 4 Apolipoprotein A-I (Apo-AI), a prominent constituent of high-density lipoproteins, contributes to pathogenesis of atherosclerosis in coronary heart disease. 5 Moreover, Apo-AI has anti-inflammatory effects by inhibiting dendritic cell maturation, suppress T cell activation, reducing cytokine production by macrophage. 6–8 It is reported that Apo-AI protects the lung by decreasing eosinophil counts in the OVA-sensitized mice after 4F treatments. 9 Genetic removal of Apo-AI can enhance pulmonary inflammation and airway hyperresponsiveness. 10 However, the direct role of Apo-AI in eosinophilic inflammation was not fully understood. The primary aims of our research were to explore the effect of Apo-AI on the function of eosinophils using both in vitro and in vivo experimentation. A total of 15 patients with persistent AR as defined by ARIA criteria and 15 healthy subjects were enrolled from our center. 11 All AR patients fulfilled the following criteria: at least 2 years' disease history, positive skin prick test or specific IgE values to at least one type of common aeroallergens. All healthy subjects have no nasal diseases and positive results to common aeroallergens. All participants included in the study did not have a history of asthma (excluded by spirometric measurements), recent respiratory system infection, or usage of anti-allergic medications, systemic or topical corticosteroids in one month before visits. Peripheral blood -Abstract Truncated-
immunology,allergy,respiratory system